Log in

NYSE:ALC - Alcon Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+1.23 (+2.01 %)
(As of 01/23/2020 06:00 AM ET)
Today's Range
Now: $62.52
50-Day Range N/A
52-Week Range
Now: $62.52
Volume1.11 million shs
Average Volume810,483 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The company also provides pharmaceutical products for elevated intraocular pressure caused by glaucoma; anti-inflammatories; anti-infective to aid in the treatment of bacterial infections and bacterial conjunctivitis; ophthalmic solutions to treat inflammation and pain associated with ocular surgery; eye inflammation and infection solutions following cataract surgery; and vitreomacular adhesion, eye and nasal allergy treatment solutions, and over-the-counter dry eye relief and ocular vitamins. In addition, it offers vision care products, such as contact lenses and lens care products; daily disposable, monthly replacement, and color-enhancing contact lenses for comfortable and convenient vision correction options; contact lens care products; multi-purpose and hydrogen-peroxide based solutions to clean, rinse, and disinfect contact lenses; rewetting drops; and daily protein removers that removes protein deposits from lenses. Alcon, Inc. was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. The company was founded in 1945 and is based in Fort Worth, Texas. Alcon, Inc. was previously operating as a subsidiary of Novartis AG. Alcon, Inc.(SWX:ALC) operates independently of Novartis AG as of April 9, 2019.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryHealth Care Facilities



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive ALC News and Ratings via Email

Sign-up to receive the latest news and ratings for ALC and its competitors with MarketBeat's FREE daily newsletter.

Alcon (NYSE:ALC) Frequently Asked Questions

What is Alcon's stock symbol?

Alcon trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALC."

How were Alcon's earnings last quarter?

Alcon AG (NYSE:ALC) released its quarterly earnings data on Tuesday, November, 19th. The healthcare company reported $0.46 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.46. The healthcare company had revenue of $1.87 billion for the quarter, compared to analyst estimates of $1.82 billion. View Alcon's Earnings History.

What price target have analysts set for ALC?

19 analysts have issued 12-month price objectives for Alcon's stock. Their forecasts range from $62.00 to $73.00. On average, they expect Alcon's stock price to reach $67.57 in the next year. This suggests a possible upside of 8.1% from the stock's current price. View Analyst Price Targets for Alcon.

What is the consensus analysts' recommendation for Alcon?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last year. There are currently 12 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alcon.

Has Alcon been receiving favorable news coverage?

News coverage about ALC stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Alcon earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news articles about the healthcare company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Alcon.

Are investors shorting Alcon?

Alcon saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,260,000 shares, an increase of 14.1% from the December 15th total of 1,980,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.5% of the shares of the company are short sold. View Alcon's Current Options Chain.

Who are some of Alcon's key competitors?

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alcon investors own include AT&T (T), Novartis (NVS), PepsiCo (PEP), Walt Disney (DIS), Pfizer (PFE), Verizon Communications (VZ), General Electric (GE), IBM (IBM), Johnson & Johnson (JNJ) and Intel (INTC).

Who are Alcon's key executives?

Alcon's management team includes the folowing people:
  • Mr. Merrick McCracken, Sr. VP of HR
  • Mr. Ed McGough, Sr. VP of Global Manufacturing and Technical Operations (Age 58)
  • Mr. David J. Endicott, Chief Exec. Officer (Age 54)
  • Mr. David Murray, Chief Financial Officer
  • Mr. Allen Baker, Chief Operating Officer and Exec. VP

Who are Alcon's major shareholders?

Alcon's stock is owned by many different of retail and institutional investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.00%), Manning & Napier Group LLC (0.00%), Calamos Advisors LLC (0.00%), Tocqueville Asset Management L.P. (0.00%), Ingalls & Snyder LLC (0.00%) and Janney Montgomery Scott LLC (0.00%).

Which institutional investors are selling Alcon stock?

ALC stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank , Broderick Brian C, Park National Corp OH, Hemenway Trust Co LLC, Chesley Taft & Associates LLC, Tocqueville Asset Management L.P., Pennsylvania Trust Co and Reilly Financial Advisors LLC.

Which institutional investors are buying Alcon stock?

ALC stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Sciencast Management LP, Clean Yield Group, Calamos Advisors LLC, Janney Montgomery Scott LLC, Patten Group Inc., Wedbush Securities Inc. and Page Arthur B.

What is Alcon's stock price today?

One share of ALC stock can currently be purchased for approximately $62.52.

MarketBeat Community Rating for Alcon (NYSE ALC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  184
MarketBeat's community ratings are surveys of what our community members think about Alcon and other stocks. Vote "Outperform" if you believe ALC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Golden Cross

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel